Khedraki Rola
Section of Advanced Heart Failure, Division of Cardiovascular Medicine, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, California, USA.
Curr Opin Cardiol. 2022 May 1;37(3):272-284. doi: 10.1097/HCO.0000000000000953. Epub 2022 Feb 25.
This review aims to serve as a practical guide for differentiating the two most common forms of cardiac amyloidosis, as well as reviewing the approach to diagnosis and management, particularly as it pertains to transthyretin cardiac amyloidosis.
Emerging literature continues to unravel new understandings and challenges in the field of cardiac amyloidosis. Although cardiac amyloidosis has historically been thought of as a 'zebra diagnosis', current evidence has shown that this is a common cause of heart failure. Furthermore, it has become increasingly apparent that earlier diagnosis leads to improved outcomes and quality of life for patients.
By leveraging an understanding of the pathophysiology leading to amyloid fibril formation, new drug therapeutics are under investigation as promising candidates for the treatment of amyloid cardiomyopathy.
本综述旨在作为区分两种最常见心脏淀粉样变性形式的实用指南，并回顾诊断和管理方法，特别是与转甲状腺素蛋白心脏淀粉样变性相关的方法。
新兴文献不断揭示心脏淀粉样变性领域的新认识和挑战。尽管心脏淀粉样变性在历史上一直被认为是一种“罕见诊断”，但目前的证据表明这是心力衰竭的常见原因。此外，越来越明显的是，早期诊断可改善患者的预后和生活质量。
通过利用对导致淀粉样纤维形成的病理生理学的理解，新的药物疗法正在研究中，有望成为治疗淀粉样心肌病的候选药物。
